Effect of sildenafil on ocular hemodynamics in 3 months regular use

Dündar, Sema Oruç; Dayanir, Yelda Özsunar; Topaloğlu, Aziz; Dündar, Mehmet; Koçak, İzzet

doi:10.1038/sj.ijir.3901416

Cited by 20 publications

(19 citation statements)

References 23 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A single oral dose of 50–100 mg sildenafil failed to impact IOP in POAG patients (Grunwald et al, 2001) and healthy volunteers (Vobig et al, 1999; Sponsel et al, 2000), but did increase blood flow in both healthy subjects (Sponsel et al, 2000; Foresta et al, 2008) and patients with systemic vascular dysfunction (Koksal et al, 2005). Also chronic treatment with sildenafil (twice per week for 3 months) failed to impact IOP (Dundar et al, 2006). It is noteworthy that the cohorts in which the effect of sildenafil on IOP was studied were of limited size (5–15 subjects).…”

Section: The No-cgmp Pathway As a Therapeutic Target For Poagmentioning

confidence: 99%

Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma

Buys

Potter

Pasquale

et al. 2014

Front. Mol. Neurosci.

View full text Add to dashboard Cite

Glaucoma is a progressive optic neuropathy characterized by visual field defects that ultimately lead to irreversible blindness (Alward, 2000; Anderson et al., 2006). By the year 2020, an estimated 80 million people will have glaucoma, 11 million of which will be bilaterally blind. Primary open-angle glaucoma (POAG) is the most common type of glaucoma. Elevated intraocular pressure (IOP) is currently the only risk factor amenable to treatment. How IOP is regulated and can be modulated remains a topic of active investigation. Available therapies, mostly geared toward lowering IOP, offer incomplete protection, and POAG often goes undetected until irreparable damage has been done, highlighting the need for novel therapeutic approaches, drug targets, and biomarkers (Heijl et al., 2002; Quigley, 2011). In this review, the role of soluble (nitric oxide (NO)-activated) and membrane-bound, natriuretic peptide (NP)-activated guanylate cyclases that generate the secondary signaling molecule cyclic guanosine monophosphate (cGMP) in the regulation of IOP and in the pathophysiology of POAG will be discussed.

show abstract

Section: The No-cgmp Pathway As a Therapeutic Target For Poagmentioning

confidence: 99%

Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma

Buys

Potter

Pasquale

et al. 2014

Front. Mol. Neurosci.

View full text Add to dashboard Cite

show abstract

“…[15][16][17] Recently, it has been suggested that sildenafil does not have any negative effects on ophthalmic blood flow velocities in erectile disfunction patients. 18,19 We also designed our study in patients with erectile dysfunction. Whereas our patients did not have a prominent vascular pathology, they might have occult vasculopathy.…”

Section: Discussionmentioning

confidence: 99%

“…5,25 On the other hand, all ocular hemodynamic studies have failed to address a decrease of orbital circulation and in the blood supply of the optic nerve head after sildenafil uptake. [15][16][17][18][19] Moreover, it was suggested that sildenafil cause to an increase in orbital blood flow velocities. Thus it is difficult to establish a causal relationship between N-AION and sildenafil usage.…”

Section: Effects Of Vardenafil On Ocular Hemodynamics 277mentioning

confidence: 98%

Effects of Vardenafil on Intraocular Pressure and Orbital Hemodynamics

Taner

Başar²,

Ünal³

et al. 2007

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

show abstract

“…In addition, we would like to note that we are aware of 5 other studies that measured the effects of sildenafil ingestion on IOP and/or ocular blood flow of human volunteers that also reported no changes in systemic blood pressure at the time the measurements were made (e.g., Dundar et al, 2006; Foresta et al, 2008; Grunwald et al, 2001b; Koksal et al, 2005; Polak et al, 2003). Overall, this suggests to us that the potential ocular hypertensive effects of sildenafil may have been overlooked.…”

Section: Discussionmentioning

confidence: 99%

Effect of sildenafil citrate on intraocular pressure and blood pressure in human volunteers

Gerometta

Alvarez

Candia

2011

Experimental Eye Research

View full text Add to dashboard Cite

Anecdotal reports have suggested that the vasodilator, sildenafil citrate, which evokes its effect via a select inhibition of PDE5, has the potential to increase intraocular pressure (IOP) in some individuals. An ocular hypertensive effect by sildenafil was also recently described in a sheep animal model. In contrast, clinical studies have not found a direct association between sildenafil ingestion (commonly consumed as Viagra) and changes in IOP. However, some such studies also reported no effects of sildenafil on systemic blood pressure (BP) at the time of the IOP determination. Given this surprising result, our purpose was to repeat a study in human volunteers in the city of Corrientes, Argentina to corroborate the effects of sildenafil on human IOP and systemic BP. For the present study, 9 healthy volunteers (male and female, 18 to 74 years old) were selected as subjects after ophthalmic and cardiovascular evaluation indicated that they exhibited normal parameters for their age. In a masked, placebo-controlled study, the subjects ingested 100 mg sildenafil citrate (provided as Vorst from Laboratorios Bernabo, Argentina) in one session, and a placebo on a second separate occasion. IOP was measured with a Goldman applanation tonometer by an ophthalmologist, and BP by a second physician, neither of whom witnessed the tablet ingestion by the volunteers, nor provided with information on the nature of the test compounds. A third individual administered the tablets. The average baseline IOP of this group of 9 was 13.1 ± 0.6 mm Hg. Subsequent to sildenafil ingestion, IOP increased by 26% to 16.5 ± 0.8 mm Hg 60 min later (p< 0.005, as paired data), and returned to control values within 2 hrs. Both systolic and diastolic BP were significantly reduced by sildenafil ingestion. At the point of maximal systemic hypotension (90 min), the systolic and diastolic pressures declined by 15% and 13%, respectively. No significant changes in IOP or BP were recorded after ingestion of the placebo. Our results suggest that sildenafil can elicit a transient IOP increase that may be of importance to patients chronically treated with PDE5 inhibitors for various vascular diseases (e.g., pulmonary hypertension). We discuss possible mechanisms by which PDE5 inhibition might lead to a rise in IOP.

show abstract

Effect of sildenafil on ocular hemodynamics in 3 months regular use

Cited by 20 publications

References 23 publications

Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma

Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma

Effects of Vardenafil on Intraocular Pressure and Orbital Hemodynamics

Effect of sildenafil citrate on intraocular pressure and blood pressure in human volunteers

Contact Info

Product

Resources

About